make it possible to directly assess human immune responses to human primary cancer cells, which recapitulate the clinical scenario with human cancers and immunotherapy [7] . A PDX model was also used in evaluating the therapeutic efficacy of CAR T cells in human B-ALL. However, PDX models are typically established in immunodeficient mice and most of them involve allogeneic and/or xenogeneic immune responses that are obviously different from cancer patients.
A group of investigators led by Yang and Sykes have made substantial effort to create humanized mouse models in which immunodeficient mice are fully reconstituted with human hematopoietic and immune systems [8] . Using these humanized mice, the Yang group has established numerous models that simulate human diseases or conditions, including a spontaneous human B-ALL model [9] . The current work by the same group utilized this human B-ALL model to evaluate the efficacy of anti-CD19 CAR-T therapy [1] . There are several unique features in this model over previously published models: 1) the recipient hu-mice have a functional human hematopoietic and immune system; 2) autologous primary B-ALL is driven by a patient-derived fusion MLL-AF9 oncogene; 3) anti-CD19 CAR-expressing human T cells are also derived by mature human T cells from the same individual; 4) the human mature T cells as a source of CAR T cells are developed in the human thymus engrafted in murine host. These features offer many advantages of this unique model including permitting the evaluation of antitumor responses in immunocompetent hosts, testing human CAR-T constructs against human primary malignance, and avoiding allogeneic responses and anti-mouse xeno-antigens. These advantages make this model highly valuable for mechanistic and preclinical studies of anti-CD19 CAR T-cell immunotherapy. In fact, the current study demonstrates the efficacy of anti-CD19 CAR-T therapy, positive correlation of CAR-T survival and expansion with B-ALL regression, and causative relationship between proinflammatory cytokines and CRS. Given this proofof-principle study, such hu-mouse models can be established to evaluate efficacy of various CAR-T cells in the treatment of relevant hematologic malignances and to study underlying mechanisms of resistance and toxicity.
While presenting many advantages, this hu-mouse model is not identical to a human host. It is obvious that non-hematopoietic tissues are mouse origin that may interfere anti-tumor responses, although the concern is mitigated in the situation of hematologic malignances. A specific limitation in evaluating CAR-T therapy using this hu-mouse model may lay in toxicity studies, as IL-6 was below the detectable level in mouse sera [1] similar to another published study using nonhumanized NSG mice [10] . The results are in sharp contrast to those from clinical trials where IL-6 has been shown to be a primary driving force for CRS. As discussed by the authors, using human cytokinetransgenic SGM3 mice that produce human SCF, GM-CSF and IL-3 might correct the defect, which remains to be investigated and confirmed. Technically, one should keep in mind that the procedure to establish such a hu-mouse model is rather convoluted. In conclusion, Jin et al. provide a preclinical mouse model that represents a close recapitulation of the human host in evaluating CAR-T therapy against hematologic malignancies to compensate the limitation of clinical trials. However, such a hu-mouse model is not identical to the human host and thus certain limitations remain.
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